26swdgu18 10.3205/26swdgu18 urn:nbn:de:0183-26swdgu181 Meeting Abstract Wenzel Wenzel Mike M

Universitätsklinikum Frankfurt, Urologie, Frankfurt, Deutschland

author Chun Chun F. F

Universitätsklinikum Frankfurt, Urologie, Frankfurt, Deutschland

author Grafen Grafen M. M

Martini Klinik, Hamburg, Deutschland

author Büttner Büttner T. T

Universitätsklinikum Bonn, Bonn, Deutschland

author Bögemann Bögemann M. M

Universitätsklinikum Münster, Münster, Deutschland

author Santoni Santoni M. M

Macerata Krankenhaus, Onkologie, Macerata, Italien

author Mandel Mandel P. P

Universitätsklinikum Frankfurt, Urologie, Frankfurt, Deutschland

author German Medical Science GMS Publishing House

Düsseldorf

610 20260610 engl This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). M0649 18 Südwestdeutsche Gesellschaft für Urologie e.V. 66. Jahrestagung der Südwestdeutschen Gesellschaft für Urologie e.V. Vortragssitzung 3: Prostatakarzinom I Koblenz 20260610 20260613 V3.2 TextIntroduction: Local treatment (LT) to the prostate demonstrated better cancer-control outcomes in combination with androgen deprivation therapy (ADT) monotherapy for low-volume metastatic-hormone sensitive prostate cancer (mHSPC). However, the association of LT with outcomes in patients receiving ADT plus androgen receptor pathway inhibitors (ARPI) across different mHSPC subtypes is under debate.Method: Relying on the multicentric international ARON-3 database, de novo low-volume mHSPC patients undergoing ARPI treatment were selected. Stratification was made according to LT vs. no LT with primary endpoint of time-on-treatment (ToT) and overall survival (OS).Results: Of 454 de novo low-volume mHSPC patients, LT was administered in addition to ARPI in 18%. In the 6-month landmark cohort, ToT was longer in patients who received additional LT, although the association did not reach statistical significance (HR 0.54, 95% CI 0.27–1.10, p=0.088). The RMST at 36 months reported a difference of 2.76 months (95% CI 0.32–6.58, p = 0.031) in the LT group compared no-LT group. OS was significantly longer in patients receiving ARPI and LT compared with ARPI alone (HR 0.09, 95% CI 0.01–0.64, p=0.016). The RMST at 36 months reported a difference of 4.67 months (95% CI 3.18-6.17, p = <0.001) in favor of the LT group. In the ridge regression, LT remained the only statistically significant predictor in ToT and OS.Conclusion: The current study suggests that adding LT to ARPIs in patients with de novo low-volume mHSPC patients may be associated with ToT and OS. The addition of LT to ARPI as the backbone of therapy may be considered in patients presenting with de novo low-volume mHSPC disease. 0 0 0 0